RE:RE:RE:RE:Guidance.....It was my best short ever, however i'm getting sick of looking at it. As i posted previously, I closed half my position at $2.50 and went long on Crh and Bus with a small short position on Peek. Realistically Cxr has enough money to stay afloat into next year but has an extremely low probability making money for commons but I think I'll close the balance of my position before the weeks out and take a flyer going long on Phm. Moneys made for the year at this point so time to have some fun. Best of luck to everyone both short and long, probably the last time I'll look at this board. Happy trading!
SpankedOnPaper wrote: Hope you made a killing on this Craigbad
Craigbad wrote: Given the latest figures, I don't see how they can even service their debt once the price cuts in the UK come through. Cash flow is on the razors edge right now of just servicing the debt and their is still the price cuts, class action law suit and the possibility of fines to finally put an end to this thing and force restructuring. It would be a miracle for this to get turned around in its current form.
GenericAdvocate wrote: If they can't offer guidance, then institutions will not ... and many CAN NOT.. buy ....
That is like saying in December, well we can't offer guidance because we don't know if Brexit is going through...
The end result is, that the investment community has NO confidence that they can service their debt without guidance.
So the share price will continue to slide. Insiders are probably short their own stock
happyretirement wrote: How could anyone expect Concordia which has a majority of their drugs sold in the UK which should finalize the Health Service Medical Supplies (Costs) Bill in the coming months and has already had many of their drugs changed from both "A & C" to "M" which puts pricing control into the hands of the DoH, no company in their right minds would make any type of estimate with the current outlook for 2017 from the UK Government.....CMA issues will be something that could be pushed out till next year and beyond as shown from previous cases such as Pfizer and others....
JMO